Sumitomo Chemical India has released a revised investor presentation concerning its financial results for Q3 and the nine months ending December 31, 2025. The updated presentation includes minor revisions to the additional Capex section, now incorporating estimated commercialization timelines for special projects. The revised document is available on the company’s website.
Q3 & 9M FY26 Performance
Sumitomo Chemical India has announced a revision to its investor presentation. The presentation focuses on the financial performance for the quarter and nine months ended December 31, 2025. The company highlights a minor revision in the presentation.
Key Updates
The primary change involves the slide pertaining to Additional Capex for Special Projects, now updated with Estimated Commercialization Timelines.
Financial Overview
Key performance indicators for the quarter (Q3FY26) compared to the same period last year (Q3FY25) include:
- Revenue: ₹568 Crs (down 12%)
- Gross Profit: ₹269 Crs (down 1%), with gross profit margin expanding to 47.4%.
- EBITDA: ₹99 Crs (down 6%), EBITDA margin improved to 17.5%.
- PAT: ₹76 Crs (down 13%)
Performance for the nine months (9MFY26) compared to last year (9MFY25) includes:
- Revenue: ₹2,555 Crs (up 3%)
- Gross Profit: ₹1,072 Crs (up 5%), with gross profit margin expanding to 42.0%.
- EBITDA: ₹537 Crs (up 5%), EBITDA margin improved to 21.0%.
- PAT: ₹432 Crs (up 6%).
Strategic Investments
The company has approved additional projects including:
- A new plant for manufacturing Herbicide intermediate at Dahej, with commercialization expected by Q2 FY2028-29.
- Fitment for additional products at the Tarapur site, expecting commercialization by Q4 FY2027-28.
Recent Launches
Recent product launches include:
- Advika
- Envoy
- Excalia Max
- Powerpull
- Herbex
- Lentigo
Guidance and Outlook
Management focuses on generating demand for high gross margin specialty products and maintaining disciplined cost control, while laying the groundwork for fiscal year 2026-27, assuming a normal monsoon season.
Source: BSE
